Compound atlas
Growth
Ipamorelin
Half-life
2h
approx. mean t½
Dose range
200–300 mcg
typical, not prescriptive
Category
Growth
primary use-case
— Overview
A selective ghrelin receptor agonist that triggers GH release without affecting cortisol or prolactin. Cleaner profile than older GHRPs.
— Mechanism of action
Selectively binds GHS-R1a (ghrelin receptor) on the pituitary. Pulsatile, biomimetic GH release.
— Typical protocol
200–300 mcg subQ, 1–3× daily, ideally on an empty stomach.
— Storage
Reconstituted: refrigerated, ~30 days.
Disclaimer
This page summarizes publicly available information. None of it constitutes medical advice, prescription, or recommendation to acquire, possess, or use any compound. Many peptides described are research chemicals not approved for human use in the EU. Consult a licensed physician.